This study aimed to investigate the association between periampullary diverticulum (PAD) and difficult biliary cannulation, as well as to evaluate the impact of different types of PAD on the cannulation success rate and adverse events.
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Introduction
Increasing the life expectancy and application of ERCP in the elderly population comes with a higher rate of the periampullary diverticulum (PAD) [1] - [3] . The incidence of PAD varies according to different diagnostic approaches and the age of the population; it is observed in 5-30% of ERCP cases [4] , [5] . Although PAD is an asymptomatic finding in ERCP patients, it could be associated with technical difficulties in the biliary cannulation and higher complication expectations [6] - [8] .
PAD is defined endoscopically as an extraluminal mucosal outpouching of the periampullary region of the duodenum [3] , [5] . It usually arises within a radius of 2-3 cm from the ampulla of Vater, and it is classified into three types according to the position of the major papilla from the endoscopic view. The first type refers to the case where the major papilla is located inside of the diverticula; the second type refers to the case where the major papilla is located at the edge of the diverticula while the third type refers to the case where the major papilla is located outside of the diverticula [1] , [3] , [8] .
There are conflicting data about the influence of PAD presence on the technical success rates and safety outcomes of ERCP. The first group of studies published in the 1980s and 1990s suggested a significantly higher rate of cannulation's failure in patients with PAD, prolonged procedure time, and an increase in adverse events' rates [9] , [10] . The second group of studies showed that there is no significant difference in the cannulation procedure success in case of presence or absence of PAD [11] - [13] . Moreover, recent prospective studies did not reveal any significant difference in either overall adverse events or a specific event, especially PEP [14] , [15] . Different techniques are reported in the literature regarding cannulation of the papilla in the presence of PAD [4] , [5] . However, more studies should be performed to evaluate the safety and efficacy of techniques used for biliary cannulation with PAD.
This prospective study aimed to investigate the association of PAD and pancreaticobiliary diseases, as well as to evaluate the impact of different types of PAD on cannulation success rate, the difficulty of biliary cannulation, and adverse events.
Data Source and Participants
This study was performed in the Institute of Digestive Endoscopy, Second Affiliated Hospital of Nanjing Medical University between July 2016 and July 2018. Patients who underwent ERCP for follow up, stent removing, or taking a biopsy were excluded. The study protocol was registered and approved by the institutional review board of the Second Affiliated Hospital of Nanjing Medical University.
Data Type
The data are collected using a designed form that reported the clinical features of each patient.
Data describing the patients' characteristics such as age, gender, indications, comorbid diseases, performed therapeutic procedures, procedure outcomes, and ERCP related adverse events were analyzed.
We classified the comorbid diseases as hypertension, cardiac diseases (ischemic heart diseases, heart failure), neurology (cerebrovascular diseases, dementia), hepatic diseases, diabetes mellitus, malignancy, renal diseases, and chronic pulmonary diseases. Also, the Charlson Comorbidities Index (CCI) score was calculated for each patient.
Indications were organized as choledocholithiasis with/without biliary pancreatitis, cholangitis, chronic pancreatitis, benign strictures, known/suspected cholangiocarcinoma, ampullary, and pancreatic carcinoma.
The ERCP procedure's success rate was defined according to the achievement of the preprocedural goal [12] . Adverse events included post-ERCP pancreatitis, perforations, cholangitis, and post-procedural bleeding evidenced by a drop-in hemoglobin >2g/dl. All adverse events were defined according to published criteria [13] .
Diagnostic Procedure
After obtaining written informed consent, all the ERCP procedures were performed by experienced endoscopists in our center using side-view duodenoscope. For PEP prevention, prophylactic octreotide dose was administered to all patients before ERCP. Patients were monitored continuously during ERCP using a pulse oximeter and electrocardiography monitoring. Supplementary oxygen was provided during conscious sedation.
Cannulation performed mainly using guidewire cannulation. The secondary techniques for difficult access cases were needle-knife fistulotomy, pancreatic stent placement, and transpancreatic biliary sphincterotomy. In recent studies, cannulation is defined as difficult if one of these conditions is satisfied; the cannulation procedure time is more than 10 minutes; the cannulation attempts on the papilla are more than ten; the pancreatic duct was cannulated more than twice [4] , [16] .
Data Analysis
Differences among different patient cohorts were determined by using Fisher's exact test for categorical variables, and non-categorical variables with the Mann-Whitney U test. Both univariate and multivariate regression models were performed with significant variables (p<0.05). Variables of potential significance (p<0.10) were entered the multivariate analysis (logistic regression analysis, enter method). Odds ratios and adjusted odds ratios were reported for each variable. All statistical analyses were performed using SPSS Statistics version 20 for Windows.
Results

Study Population
A total of 952 patients who underwent ERCP during the study period have entered the study ( Fig. 1 ). Of these, 316 patients did not meet the initial study requirements and were excluded from the analysis; this includes the patients of follow-up (166), removing stents (114), and taking a biopsy (36). Accordingly, only 636 patients were analyzed and divided based on PAD presence into two groups; the first group A included patients with PAD; 126 patients of overall cases, the second group B included 510 patients without PAD (Table 1) . Later, the PAD patients were filtered based on the types of PAD; 93 patients had PAD type 3; 18 patients had type 2, and 15 patients had type 1 (see Table 2 ).
Patient Characteristics
Based on the PAD's presence, 19 .8% of patients were considered in the PAD group (group A) with an average age of 72.63±1 2.12 (see Table 1 ). The control group included 510 patients with an average age of 63.47±17.15. A single diverticulum was found in 84.2% of patients with PAD, 15 .8% had two diverticulum or more. There was no significant difference in patients' gender in both groups, with a male percentage (57.9% vs. 51.4%, p=0.175). The presence of PAD was not associated with differences in the overall comorbidities (p=0.078) and the proportion of patients with CCI ≥2 (23.8% vs. 19.8%, p=0.300).
Figure 1 ERCP sample breakdown
In the PAD patients' group, significantly higher rates of biliary stones (88.1% vs. 79.4%, p=0.044), biliary pancreatitis ( There was no significant difference between the two groups in the adverse event rate, especially post-ERCP pancreatitis (4.8% vs. 5.1% p=0.535) and perforation (0% vs. 0.6%, p= 0.511). Also, no significant difference was found in Post-ERCP bleeding rate, although there was a higher rate of bleeding with the presence of PAD (3.2% vs. 1.8% p=0.304). In this study, we revealed clinical characteristics according to the PAD subtypes. The most frequent diagnosed subtype of PAD was type 3, with 73.8% of overall PAD cases, followed by type 2 (14.3%), and type 1 (11.9%). The correlation between PAD subtypes and clinical characteristics was reported in Table 2 .
We noted that patients with type 2 had a significantly higher rate of biliary pancreatitis as an indication of ERCP (6.7% vs. 27.8% vs. 7.5%, p<0.001). In addition, cholangitis was more common in patients with type 1(26.7% vs. 11.1% vs. 12.9%, p=0.030).
Patients with type 1 had a significant longer procedure time (p=0.032), cannulation time (p=0.001), and a higher rate of cannulation difficulty (p<0.001). 
Risk Factors of Adverse Events
In the second multivariate model, we studied the factors that were found to be related to the presence of PAD, as it is shown in 
Discussion
The current study focused on the association of different types of periampullary diverticulum with ERCP cannulation success. Also, it studied the difficulty and safety of papillary cannulation in the presence of PAD. This stricture was found in 19.8% of our participants, which was acceptable comparing with previous reports (3%-25%). The detailed description of the PAD showed that type 3 was the most common subgroup, followed by type 1 and type 2. Regarding overall comorbidities, using a cutoff of CCI ≥2, no significant difference was seen between the two groups.
Several studies have considered PAD as an essential risk factor of biliary stones formation [17] - [21] , which is also suggested by our results. We noted that almost all PAD patients with type 1 have biliary stones, which were more common compared with types 2 and 3, although it did not reach a statistical difference. A possible explanation for the association between PAD and choledocholithiasis can be related to the spasm of Oddi sphincter caused by diverticula. This dysfunction in the sphincter of Oddi causes increasing in biliary tract pressure and intestinal content reflux leading to biliary stone formation. Besides, the possibility of distal CBD part compression could cause functional biliary stasis, which may produce cholangitis and incidence of biliary stones. Thus, our study also supports the fact that cholangitis and biliary pancreatitis are more common in the presence of PAD.
Besides, we found a lower proportion of periampullary malignancy, especially ampullary carcinoma, in group A compared with group B, and a negative correlation between malignancy and PAD. This finding is supported by prior studies that found that neoplastic lesions as colorectal and periampullary carcinoma were less common in patients with diverticular disease [22] , [23] .
Regarding ERCP outcomes, previous studies have shown different results regarding the procedure success rates and visualization rates of main biliary structures in patients with PAD.
The experience of the endoscopists, using different cannulation techniques, patients' characteristics, and study design can be factors that reveal various findings regarding cannulation success and difficulty in patients with PAD [10]- [13] . In our study, we did not observe significant differences in ERCP success rate and procedure duration between the two groups, although the PAD group was more likely to have cannulation difficulty and longer cannulation time. Furthermore, cannulation in PAD patients with type 1, in which papilla is located inside the diverticula, was more challenging and has been associated more frequently with cannulation difficulty.
In the literature, several retrospective studies described different cannulation techniques in the presence of a PAD [24] - [27] . The most frequently described techniques in those studies were pancreatic duct stent placement, followed by needle-knife fistulotomy, and cap-assisted forwardviewing endoscopy.
Our study had prospectively compared the efficacy of access common biliary duct by different methods in the presence of PAD. All cannulation techniques were effective in achieving successful biliary access in the two groups without significant differences in overall adverse events. Standard cannulation using guidewire cannulation with sphincterotomy was the most frequent cannulation technique in both groups. Needle knife fistulotomy with or without pancreatic duct stent placement was a suitable option for difficult cannulation cases and more frequent in the PAD group, especially in type 1, without significant differences. Trans-pancreatic biliary sphincterotomy was also available to cannulate the papilla in the presence of PAD, and patients with type 2 had a higher frequency to use this technique.
Regarding finding the factors that affect cannulation difficulty, using a multivariate analysis model, we did not find any increase in the odds of cannulation difficulty with advanced age, high CCI, and male gender. However, an increased odds of difficult cannulation was noted with PAD type 1 (AOR=11.2) and with the indication of cholangitis (AOR=0.50) and choledocholithiasis (AOR=0.20).
In the relation between the presence of PAD and adverse events, different results have been reported according to older and more recent literature [14] , [15] , [28] . Our study, as well as most recent studies, had not found any significant difference in overall adverse events or a specific event, especially PEP [4] , [14] . However, we found that patients of type 1 had a higher frequency of PEP than patients with type 2 or type 3. That is related to the specific location of type1, which may cause pancreatic duct compression and pancreatitis as a result. In addition, a higher rate of bleeding was related to patients with type 3.
The main strength of this study is its prospective nature, and to the best of our knowledge, there are fewer studies that focused on difficult cannulation and its relation with PAD. There are few limitations in this study; first is that the data were collected at a single center; second is the rarity of specific adverse events though our sample size patients were reasonable.
Conclusion
This study has shown that although difficult cannulation ERCP is more common in patients with PAD, procedure time and successful cannulation rates are similar to those without PAD. As well as using different techniques is well tolerated with a similar rate of post ERCP pancreatitis in patients with and without PAD. Interestingly, our study demonstrated that the presence of PAD type 1, biliary stones, and cholangitis are correlated with difficult cannulation.
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